Tekmira to merge with OnCore, to create major hep B company

14 January 2015

Shares of Tekmira Pharmaceuticals (Nasdaq: TKMR) leapt as much as 50%, after it announced a merger with privately-held US biotech firm OnCore Biopharma, to create a new, major global hepatitis B virus (HBV) company.

Tekmira, a leading developer of RNA interference (RNAi) therapeutics, will acquire OnCore, a biopharmaceutical company dedicated to discovering, developing and commercializing an all-oral cure for patients suffering from chronic hepatitis B virus (HBV) infection, in an all stock deal, whereby the latter will become a wholly-owned subsidiary of Tekmira.

Transaction details

On closing of the transaction, OnCore shareholders will hold around 50% of the total number of outstanding shares of capital stock of Tekmira, calculated on a fully-diluted and as-converted basis using the treasury stock method. The implied market value of the combined company, based on the closing price of Tekmira common shares on the Nasdaq Global Market on January 9, 2015, is about $750 million.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK